Overview

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Phase:
PHASE2
Details
Lead Sponsor:
Ruijin Hospital
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.